...
首页> 外文期刊>biomolecules >Podophyllotoxin: History, Recent Advances and Future Prospects
【24h】

Podophyllotoxin: History, Recent Advances and Future Prospects

机译:鬼臼毒素:历史、最新进展和未来展望

获取原文
获取原文并翻译 | 示例

摘要

Podophyllotoxin, along with its various derivatives and congeners are widely recognized as broad-spectrum pharmacologically active compounds. Etoposide, for instance, is the frontline chemotherapeutic drug used against various cancers due to its superior anticancer activity. It has recently been redeveloped for the purpose of treating cytokine storm in COVID-19 patients. Podophyllotoxin and its naturally occurring congeners have low bioavailability and almost all these initially discovered compounds cause systemic toxicity and development of drug resistance. Moreover, the production of synthetic derivatives that could suffice for the clinical limitations of these naturally occurring compounds is not economically feasible. These challenges demanded continuous devotions towards improving the druggability of these drugs and continue to seek structure-optimization strategies. The discovery of renewable sources including microbial origin for podophyllotoxin is another possible approach. This review focuses on the exigency of innovation and research required in the global RD and pharmaceutical industry for podophyllotoxin and related compounds based on recent scientific findings and market predictions.
机译:鬼臼毒素及其各种衍生物和同系物被广泛认为是广谱药理活性化合物。例如,依托泊苷因其卓越的抗癌活性而成为用于治疗各种癌症的一线化疗药物。它最近被重新开发,用于治疗 COVID-19 患者的细胞因子风暴。鬼臼毒素及其天然存在的同系物生物利用度低,几乎所有这些最初发现的化合物都会引起全身毒性和耐药性的发展。此外,生产足以满足这些天然化合物临床局限性的合成衍生物在经济上是不可行的。这些挑战要求我们不断致力于提高这些药物的成药性,并继续寻求结构优化策略。发现可再生资源,包括鬼臼毒素的微生物来源是另一种可能的方法。本综述基于最近的科学发现和市场预测,重点关注全球研发和制药行业对鬼臼毒素和相关化合物所需的创新和研究的紧迫性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号